Biotherapeutics are expanding the arsenal of therapeutics available for treating and
preventing disease. Although initially thought to have limited side effects due to the …

Human interferon (IFN)–α is the standard therapy for chronic hepatitis C to prevent its
progression to liver cirrhosis and hepatocellular carcinoma. Thrombocytopenia is one of the …

Hepatitis C virus (HCV) is a widespread infection with an estimated prevalence of at least
1.8% in the American population and is a leading cause of liver-related morbidity and …

Retreatment with telaprevir, pegylated interferon, and ribavirin resulted in an 80% sustained
virological response rate in HIV/hepatitis C virus–coinfected patients, despite 20% of …

Objectives: Autoantibodies were studied in a well-characterized cohort of children with
chronic hepatitis C during treatment with pegylated interferon and ribavirin to assess the …

A 66-year-old woman developed systemic sclerosis (SSc) after receiving interferon
alphacon-1 (IFNαcon-1; consensus interferon) therapy for chronic hepatitis C. She suffered …

Since the identification of hepatitis C virus (HCV) in 1989 as a causative agent for a number
of the extrahepatic alterations related to HCV infection an underlying immune mediated …

We report a case of severe thrombocytopenia following pegylated interferon-α 2a (Peg-IFN-
α 2a) treatment of hepatitis C virus infection and summarize the clinical characteristics of 16 …

Background Autoimmune thrombocytopenic purpura is an immunological disorder
characterized by increased platelet destruction due to presence of anti-platelet …

Pegylated interferon (PEG-IFN) alpha and ribavirin therapy has become the standard
treatment in chronic hepatitis C virus (HCH)-infected patients. While thrombocytopenia …